Key facts
- Notable investors include Shanghai Fir Creek Private Equity Fund Management, Shihezi Longtai Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Saihe Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Saihe Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Saihe Bio
Developer of innovative drugs designed for the radiopharmaceutical field. The company's products mainly focus on targeted alpha particle radiotherapy to improve patient survival rates for liver, pancreatic, thyroid, ovarian, lung, etc., providing customers with reliable and innovative drugs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Saihe Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Saihe Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Saihe Bio in its N-PORT filings yet. We sweep new filings monthly.